Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from Phase 2 study shows well-tolerated treatment with significant frataxin ...

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced this week that the U.S. Food and Drug Administration ...

Larimar will continue the open label extension study in Friedreich’s ataxia with results expected in Q4 this year.

U.S. stocks were mostly higher, with the Dow Jones index gaining around 50 points on Tuesday. Shares of XPeng Inc. XPEV rose ...

Larimar Therapeutics’ Friedreich’s ataxia program is free at last, with the FDA fully lifting a clinical hold that had ...

Leerink Partners raised the price target for the Larimar Therapeutics Inc (NASDAQ:LRMR) stock to “an Outperform”. The rating was released on April 03, 2024, according to finviz. The research report ...

Shares of Larimar Therapeutics, Inc.. (NASDAQ:LRMR) rose sharply in today's pre-market trading after the company announced ...

Asian stock markets today closed in the red. China’s Shanghai Composite Index (SHCOMP) closed down -0.42% and Japan’s Nikkei 225 Stock Index (NIK) closed down -0.31%.

Stock futures were little changed on Tuesday with consumer spending in focus, as a slew of earnings from retailers were due. Expected results from Lowe's, Macy's, AutoZone and Urban Outfitters may ...

(RTTNews) - Larimar Therapeutics, Inc. (LRMR) Tuesday announced that FDA has removed the partial clinical hold placed on its nomlabofusp or CTI-1601, a clinical program targeting treatment of patients ...

Larimar (LRMR) said the FDA has removed a partial clinical hold on its nomlabofusp clinical program following a review of ...

By Stephen Nakrosis Shares of Larimar Therapeutics were trading higher in after-hours action Monday, following news the U.S. Food and Drug Administration ...